Published in Endocr Pract on June 14, 2006
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause (2008) 1.74
Hormone therapy and skeletal muscle strength: a meta-analysis. J Gerontol A Biol Sci Med Sci (2009) 1.17
Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies. Drug Des Devel Ther (2009) 0.94
"I should live and finish it": a qualitative inquiry into Turkish women's menopause experience. BMC Fam Pract (2009) 0.83
Combined hormone therapy at menopause and breast cancer: a warning--short-term use increases risk. J Clin Oncol (2009) 0.77
Predictors of bone mineral density testing among older women on Medicare. Osteoporos Int (2016) 0.76
The relationship between endogenous androgens and body fat distribution in early and late postmenopausal women. PLoS One (2013) 0.76
The role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms. Int J Gen Med (2010) 0.76
Estrogen formulations and beauty care practices in Japanese women. Int J Womens Health (2012) 0.75
Clinical evaluation of Ashokarishta, Ashwagandha Churna and Praval Pishti in the management of menopausal syndrome. Ayu (2012) 0.75
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril (2008) 5.31
Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab (2006) 4.56
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab (2002) 3.06
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract (2004) 2.69
Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab (2010) 2.48
High-sensitivity tandem mass spectrometry assay for serum estrone and estradiol. Am J Clin Pathol (2008) 2.47
Breast cancer: relationship between menopausal symptoms, physiologic health effects of cancer treatment and physical constraints on quality of life in long-term survivors. J Clin Nurs (2005) 2.43
American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract (2003) 2.42
Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab (2004) 2.39
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
Osteoporosis, teriparatide, and dosing of calcium and vitamin D. N Engl J Med (2005) 2.22
Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res (2004) 2.21
Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci (2007) 2.15
Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. Clin Chem (2013) 1.96
Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab (2004) 1.96
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92
Free thyroid hormones in serum by direct equilibrium dialysis and online solid-phase extraction--liquid chromatography/tandem mass spectrometry. Clin Chem (2008) 1.87
Male obesity and alteration in sperm parameters. Fertil Steril (2008) 1.84
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res (2002) 1.79
National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom (2008) 1.76
Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum (2002) 1.74
Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med (2005) 1.72
American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. Endocr Pract (2004) 1.69
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res (2005) 1.68
Diagnosis and management of vertebral fractures in elderly adults. Am J Med (2002) 1.68
Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab (2004) 1.67
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol (2005) 1.62
Impact of male obesity on infertility: a critical review of the current literature. Fertil Steril (2008) 1.56
Fat embolism syndrome. Am J Med Sci (2008) 1.55
Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet (2002) 1.54
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
Premicroalbuminuria in women with polycystic ovary syndrome: a metabolic risk marker. Endocr Pract (2008) 1.51
Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res (2006) 1.45
Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin Chem (2010) 1.44
Thyroid disease associated with exposure to the Nevada nuclear weapons test site radiation: a reevaluation based on corrected dosimetry and examination data. Epidemiology (2006) 1.44
An aromatase polymorphism modulates the relationship between weight and estradiol levels in obese men. Fertil Steril (2009) 1.43
Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstet Gynecol (2011) 1.43
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2007) 1.43
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J Clin Endocrinol Metab (2014) 1.41
Bone mineral density testing: is a T score enough to determine the screening interval? Cleve Clin J Med (2013) 1.39
Effect of precision error on T-scores and the diagnostic classification of bone status. J Clin Densitom (2007) 1.38
Review of treatment modalities for postmenopausal osteoporosis. South Med J (2005) 1.37
Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med (2008) 1.29
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res (2012) 1.29
Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin (2004) 1.28
Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions. J Clin Densitom (2006) 1.26
Liquid chromatography tandem mass spectrometry for analysis of steroids in clinical laboratories. Clin Biochem (2010) 1.24
Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA (2002) 1.22
Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res (2011) 1.22
Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck (2009) 1.21
Effect of Roux-en-Y gastric bypass surgery on the sex steroids and quality of life in obese men. J Clin Endocrinol Metab (2009) 1.21
Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res (2014) 1.19
Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom (2004) 1.18
Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg (2003) 1.16
Prior oral contraception and postmenopausal fracture: a Women's Health Initiative observational cohort study. Fertil Steril (2005) 1.13
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int (2005) 1.09
Exercise and pharmacological countermeasures for bone loss during long-duration space flight. Gravit Space Biol Bull (2005) 1.08
Secondary osteoporosis: a review of the recent evidence. Endocr Pract (2006) 1.07
Pre-analytical errors: everything that happens to the specimen up to the point of testing. Fertil Steril (2002) 1.07
Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008. J Bone Miner Res (2011) 1.07
An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Ann Rheum Dis (2012) 1.06
Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. J Clin Densitom (2006) 1.04
Development and performance evaluation of a tandem mass spectrometry assay for 4 adrenal steroids. Clin Chem (2006) 1.04
Osteoporosis screening in postmenopausal women 50 to 64 years old: comparison of US Preventive Services Task Force strategy and two traditional strategies in the Women's Health Initiative. J Bone Miner Res (2014) 1.03
Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom (2006) 1.03
Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res (2009) 1.03
Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol (2007) 1.03
Postmenopausal osteoporosis. Curr Opin Endocrinol Diabetes Obes (2013) 1.02
Bisphosphonates for postmenopausal osteoporosis. Bone (2011) 1.01
Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg (2002) 1.00
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause: executive summary of recommendations. Endocr Pract (2011) 1.00
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab (2014) 0.99
Low-fat, increased fruit, vegetable, and grain dietary pattern, fractures, and bone mineral density: the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr (2009) 0.98
Bisphosphonates in the treatment of osteoporosis. Endocrinol Metab Clin North Am (2012) 0.98
Skeletal health in long-duration astronauts: nature, assessment, and management recommendations from the NASA Bone Summit. J Bone Miner Res (2013) 0.98
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin (2005) 0.98
A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril (2002) 0.96
Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol (2008) 0.96
Sleep apnea, reproductive hormones and quality of sexual life in severely obese men. Obesity (Silver Spring) (2011) 0.96
Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2011) 0.96